Results 61 to 70 of about 54,917 (299)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?

, 2023
There is a need for innovative pharmaceutical intervention in light of the increasing prevalence of metabolic disease and cardiovascular disease. The kidneys’ sodium-glucose cotransporter 2 inhibitors (SGLT2) receptors are targeted to reduce ...
Camelia, Nicolae, Emil, Tufanoiu, Popescu Razvan-Ionut, Razvan-Ionut, Popescu, Tiberiu, Nanea Ioan, Nicolae Camelia, Tufanoiu Emil, Munteanu Madalina Andreea, Lucia, Ciobotaru, Ciobotaru Lucia, Andreea, Munteanu Madalina, Surabhi, Swarnkar, Nanea Ioan Tiberiu, Swarnkar Surabhi   +13 more
core   +1 more source

Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence

British Journal of Clinical Pharmacology, EarlyView.
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza, Andrej Belancic, Jens Jordan, Alberto Esteban, Anna Oliveras, Ryan McNally, Panagiota Anyfanti, Jorie Versmissen, María S. Fernández‐Alfonso, Vasilios Kotsis, Thomas Weber, Alexandre Persu, Reinhold Kreutz   +12 more
wiley   +1 more source

Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study

Frontiers in Cardiovascular Medicine, 2022
BackgroundSodium-glucose co-transporter 2 (SGLT2) inhibitors has been shown with cardiovascular benefit in type 2 diabetes mellitus (T2DM) patients. However, its osmotic diuresis still concern physicians who may look for possible electrolyte imbalance ...
Victor Chien-Chia Wu, Kai-Pin Chiu, Chun-Li Wang, Chiu-Yi Hsu, Hui-Tzu Tu, Yu-Tung Huang, Chih-Hsiang Chang, Chien-Hao Huang, Chang-Fu Kuo, Chang-Fu Kuo, Shao-Wei Chen, Shao-Wei Chen, Pao-Hsien Chu, Shang-Hung Chang, Shang-Hung Chang, Shang-Hung Chang   +15 more
doaj   +1 more source

SGLT2 inhibitors in cardiovascular medicine [PDF]

European Heart Journal - Cardiovascular Pharmacotherapy, 2021
Varzideh, Fahimeh, Kansakar, Urna, Santulli, Gaetano   +2 more
openaire   +3 more sources

The potential impact of H1 antihistamines on clinical outcomes in NSCLC patients undergoing EGFR‐TKIs treatment

British Journal of Clinical Pharmacology, EarlyView.
Background Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR‐TKIs) have substantially improved outcomes in non‐small cell lung cancer (NSCLC); however, the development of treatment resistance remains a major clinical challenge. This study examines the association between concomitant prescriptions of H1‐antihistamines (H1AHs) and ...
Van Thuan Nguyen, Ngoc Hoang Le, Nhu Quynh Phan, Toan Trung Duong, Le Thi Anh Thu, Hsuan‐Chia Yang, Chih‐Wei Huang, Min‐Huei Hsu, Jason C. Hsu, Chien‐Tien Su, Phung‐Anh Nguyen   +10 more
wiley   +1 more source

Inhibition of Sodium-Glucose Cotransporter-2 during Serum Deprivation Increases Hepatic Gluconeogenesis via the AMPK/AKT/FOXO Signaling Pathway [PDF]

Endocrinology and Metabolism
Background Sodium-dependent glucose cotransporter 2 (SGLT2) mediates glucose reabsorption in the renal proximal tubules, and SGLT2 inhibitors are used as therapeutic agents for treating type 2 diabetes mellitus.
Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Yu-Mi Lim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee   +8 more
doaj   +1 more source

The Brains Behind SGLT2 Inhibition [PDF]

Diabetes Care, 2022
Haiko Schlögl, Michael Stumvoll
openaire   +3 more sources

SGLT2 Inhibitor-Related Polycythemia in a Patient with Chronic Heart Failure:A Potential Severe Adverse Event

, 2023
According to the current heart failure guidelines, SGLT2 (sodium glucose cotransporter 2) inhibitors are increasingly prescribed in patients with heart failure (HF).1 However, SGLT2-inhibitors are known to increase hemoglobin (Hb) and hematocrit (Ht ...
Bruwiere, Ewout, Bos, Sven, Tukker, Martijn, Caliskan, Kadir; id_orcid   +3 more
core   +1 more source

Pharmacokinetic and pharmacodynamic interaction of enavogliflozin, a sodium‐glucose cotransporter 2 inhibitor, with glimepiride and metformin in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims Enavogliflozin, a sodium‐glucose cotransporter 2 inhibitor, is expected to be coadministered with antihyperglycaemic drugs with different mechanisms of action. This study aimed to investigate the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between enavogliflozin, glimepiride and metformin.
Kyungrin Chang, Yoonjin Kim, Daye Jung, Jae Min Cho, Joo‐Youn Cho, SeungHwan Lee   +5 more
wiley   +1 more source

Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure? [PDF]

, 2022
Despite the constant improvement of therapeutical options, heart failure (HF) remains associated with high mortality and morbidity. While new developments in guideline-recommended therapies can prolong survival and postpone HF hospitalizations, impaired ...
Voorrips, Suzanne N., Pablo I. Sánchez-Aguilera, Huitzilihuitl Saucedo-Orozco, Sánchez-Aguilera, Pablo I., Boer, Rudolf A. De, Saucedo-Orozco, Huitzilihuitl, Van der Meer, Peter, Westenbrink, B. Daan, De Boer, Rudolf A., Westenbrink, B. Daan; id_orcid, Rudolf A. De Boer, Peter Van der Meer, B. Daan Westenbrink, Suzanne N. Voorrips, Saucedo-Orozco, Huitzilihuitl; id_orcid   +14 more
core   +1 more source